3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
7
Unspecified Adult Solid Tumor, Protocol Specific
4
Lymphoma, Mantle-Cell
4
Colorectal Neoplasms
4
Rectal Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Glioblastoma
3
Waldenstrom Macroglobulinemia
2
Squamous Cell Carcinoma of Head and Neck
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Extranodal NK-T-Cell
2
Leukemia, Prolymphocytic
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Hodgkin Disease
2
Gliosarcoma
2
Glioma
2
Congenital Abnormalities
2
Colonic Neoplasms
2
Burkitt Lymphoma
2
Interventions
Temozolomide
10
Radiotherapy
10
Bevacizumab
6
Everolimus
5
ribociclib
3
Radiation
3
Panobinostat
3
Dasatinib
3
Valproic Acid
2
TIC10 compound
2
Re-Irradiation
2
Nivolumab
2
Mebendazole
2
Irinotecan
2
Gemcitabine
2
GDC-0084
2
Etoposide
2
Erlotinib Hydrochloride
2
Diphtheria-Tetanus Vaccine
2
Cyclophosphamide
2
Cilengitide
2
Cetuximab
2
vandetanib
1
tovorafenib
1
temsirolimus
1
spartalizumab
1
sargramostim
1
reolysin
1
pembrolizumab
1
ovex
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Diffuse Intrinsic Pontine Glioma
×
Pharmacogenomic Testing
×
Clear all
NCT01165333
2026-03-16
CILENT
Centre Oscar Lambret
Phase 1
Completed
32 enrolled